The cardiovascular effects of MPV 295 [4(5)-2-(2,6-dimethylphenyl)ethylimidazole], a new antihypertensive agent with alpha 2-adrenoceptor agonistic properties.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002415:Cats; D003000:Clonidine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D015016:Yohimbine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; C038226:4(5)-2-(2,6-dimethylphenyl)ethylimidazole; D003000:Clonidine; D011224:Prazosin